Opioids News and Research

RSS

An opioid is a chemical that works by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. The receptors in these two organ systems mediate both the beneficial effects and the side effects of opioids.

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action.

28 Sep 2015

New countries join ESMO Designated Centre of Integrated Oncology and Palliative Care

Patient eligibility for opioids is seriously restricted in some countries, with the highest rate of limited access to palliative care found in the Middle East, followed by Latin America and the Caribbean and Asia. Data are revealed by the ESMO Global Opioid Policy Initiative (GOPI) which identifies barriers to the availability and accessibility of essential pain relieving medication worldwide.

26 Sep 2015

New guideline on the use of prescription medications for treatment of opioid addiction

Medications play an important role in managing patients with opioid use disorders, but there are not enough physicians with the knowledge and ability to use these often-complex treatments.

25 Sep 2015

TSRI study reveals key morphine regulator that may help develop less-addictive pain medications

Once used in the 18th century as currency to reverse the trade imbalance between China and Britain, opiates that contain morphine have been misunderstood almost continually ever since.

23 Sep 2015

Study reports use of new psychoactive drugs in US nationally representative survey

In recent years, there has been an increase in emergence and use of a variety of new drugs, so-called "novel psychoactive substances" (NPS) in the US and worldwide.

16 Sep 2015

New treatment protocol can improve outcomes for babies with neonatal abstinence syndrome

A new protocol to treat babies born in withdrawal from drugs can be used widely to improve outcomes for these babies. The protocol reduces length of stay and the duration of treatment with opioids that are used therapeutically to wean babies off of drugs.

14 Sep 2015

Study shows half of adolescents misuse their prescription drugs

Although prescription drug misuse is on the decline among adolescents, one in two patients tested between the ages of 10 and 17 years are not using their medications appropriately, potentially putting their health at risk, according to an analysis by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.

From Quest Diagnostics 11 Sep 2015

Psychosis, hepatitis C infection are greatest risk factors for mortality in marginalized Vancouver residents

Marginalized residents of Vancouver's Downtown Eastside are dying at more than eight times the national average, and treatable conditions are the greatest risk factors for mortality, researchers at the University of British Columbia have found.

11 Sep 2015

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.

9 Sep 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

AfPA’s video highlights new technology and pill formulations that deter individuals from abusing opioids

Today the Alliance for Patient Access released a new white board video, "A Prescription for Reducing Opioid Abuse." The video, released to coincide with National Pain Awareness Month, highlights new technology and innovative pill formulations that deter individuals from abusing opioids.

9 Sep 2015

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar Therapeutics announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany.

1 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

Education can empower clinicians to safely prescribe opioids for chronic pain sufferers

Educating clinicians on how to safely prescribe opioids can help decrease opioid misuse among chronic pain sufferers.

27 Aug 2015

Variations in opioid receptor genes linked to neonatal abstinence syndrome severity in newborn babies

A new study led by researchers at Boston Medical Center indicates that variations in opioid receptor genes are associated with more severe neonatal abstinence syndrome (NAS) in newborn babies. The findings, published online in Drug & Alcohol Dependence, could help lead to the development of individualized treatment plans tailored to each infants' risk of requiring medication to curb their NAS symptoms, which could help improve these patients' outcomes and reduce how long some stay in the hospital.

26 Aug 2015

AMA Task Force to Reduce Opioid Abuse announces national recommendations to address opioid crisis

Opioid abuse is a serious public health problem that has reached crisis levels across the United States, with 44 people dying each day from overdose of opioids, and many more becoming addicted. Recognizing the urgency and serious impact of this issue on the health of hundreds of thousands of patients across the country, today the American Medical Association Task Force to Reduce Opioid Abuse announced the first of several national recommendations to address this growing epidemic.

25 Aug 2015

Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

In response to the growing opioid crisis, several states, including Massachusetts and Rhode Island, have granted pharmacists the authority to provide naloxone rescue kits without a prescription to at-risk patients. This model of pharmacy-based naloxone (PBN) education and distribution is one of the public health strategies currently being evaluated at hundreds of pharmacies in both states to determine the impact on opioid overdose death rates.

25 Aug 2015

Three medical oncologists to receive ESMO's acclaimed awards

The European Society for Medical Oncology, the leading European professional organisation for advancing medical oncology, announced today the three exceptional medical oncologists who will receive its acclaimed awards.

24 Aug 2015

Opioids produced by yeast; revealing the potential for cheaper pain relief

Researchers at Stanford University have genetically engineered yeast so it produces hydrocodone, a semi-synthetic opioid analgesic used in the United States for relief of moderate to severe pain.

14 Aug 2015

Opioids News and Research

Further Reading

FDA accepts Braeburn's resubmission of Probuphine NDA for review

New countries join ESMO Designated Centre of Integrated Oncology and Palliative Care

New guideline on the use of prescription medications for treatment of opioid addiction

TSRI study reveals key morphine regulator that may help develop less-addictive pain medications

Study reports use of new psychoactive drugs in US nationally representative survey

New treatment protocol can improve outcomes for babies with neonatal abstinence syndrome

Study shows half of adolescents misuse their prescription drugs

Psychosis, hepatitis C infection are greatest risk factors for mortality in marginalized Vancouver residents

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

AfPA’s video highlights new technology and pill formulations that deter individuals from abusing opioids

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Education can empower clinicians to safely prescribe opioids for chronic pain sufferers

Variations in opioid receptor genes linked to neonatal abstinence syndrome severity in newborn babies

AMA Task Force to Reduce Opioid Abuse announces national recommendations to address opioid crisis

Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

Three medical oncologists to receive ESMO's acclaimed awards

Opioids produced by yeast; revealing the potential for cheaper pain relief

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News